A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy
Starting soon · Not applicable
Conditions studied: Diabetes Mellitus
In brief
This is a single-arm, open-label clinical trial designed to assess the safety and therapeutic efficacy of iPSC-derived islet cell infusion in patients with diabetes mellitus.
Key facts
- Study ID
- NCT07464119
- Run by
- Peking University First Hospital
- People needed
- 30
- Starts
- 2026-03-16
- Expected to finish
- 2033-12-31
- Last updated by the study team
- 2026-03-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Peking University First Hospital — Beijing, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.